Brief: uniQure Announces Positive Interim Data Update From Phase I/II Trials Of AMT-130 For Huntington’s Disease
09/07/2024 12:34
July 9 (Reuters) - Uniqure NV UQ1.F :
* UNIQURE ANNOUNCES POSITIVE INTERIM DATA UPDATE
DEMONSTRATING
SLOWING OF DISEASE PROGRESSION IN PHASE I/II TRIALS OF AMT-130
FOR HUNTINGTON’S DISEASE
* UNIQURE NV - HIGH-DOSE AMT-130 SHOWS 80% SLOWING OF
DISEASE
PROGRESSION
* UNIQURE NV: IN H2, EXPECTS TO HOLD TYPE B,
MULTI-DISCIPLINARY
RMAT MEETING WITH U.S. FDA
Source text for Eikon: ID:nGNX9y1jHp
Further company coverage: UQ1.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on uniQure
See all newsuniQure tumbles after updated Huntington's disease gene therapy data
UniQure plunges as Huntington's trial data disappoints investors (updated)
uniQure tumbles after updated Huntington's disease gene therapy data
UniQure's Huntington's therapy fails to significantly slow disease progression in trial
uniQure seeks US approval for Huntington's gene therapy after FDA reversal